{"product_id":"gild-bcg-matrix","title":"(GILD) Gilead Sciences, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Gilead Sciences, Inc. BCG Matrix is a company-specific strategy tool used to assess its products or business units as Stars, Cash Cows, Question Marks, or Dogs. The page already shows a real preview of the actual analysis, so you can see the format and content before you buy. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiktarvy, $13.4B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiktarvy generated $13.4B in 2024 sales, making it Gilead Sciences, Inc.'s biggest product and top HIV brand. In BCG terms, it is a Star: the core growth engine in a still-expanding HIV treatment market. Strong volume, premium pricing, and broad use in first-line therapy keep cash generation and share high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDescovy PrEP, about $2.4B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDescovy PrEP is a Star for Gilead Sciences, Inc., with about $2.4 billion in 2024 sales and strong U.S. demand. The HIV PrEP market is still growing as screening and uptake improve, and Gilead keeps the dominant branded position in this niche. That scale and category leadership support high growth, even as competition stays limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYescarta, about $1.7B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYescarta is a Star in Gilead Sciences, Inc.’s BCG Matrix: it delivered about $1.7B in 2024 sales and remains the leading CAR-T therapy in large B-cell lymphoma. Its growth is helped by use earlier in treatment and wider adoption across hematology centers. This makes Yescarta one of Gilead Sciences, Inc.’s fastest-growing oncology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrodelvy, about $1.3B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrodelvy fits a Star profile in Gilead Sciences, Inc. BCG Matrix: 2024 sales were about $1.3B, and its use is expanding in metastatic breast and bladder cancers. Oncology is growing faster than Gilead Sciences, Inc.'s legacy antivirals, so Trodelvy is still building share across new tumor settings. That mix supports high growth, with room to scale if uptake stays strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 sales: about $1.3B\u003c\/li\u003e\n\u003cli\u003eADC in breast and bladder cancers\u003c\/li\u003e\n\u003cli\u003eFaster growth than antivirals\u003c\/li\u003e\n\u003cli\u003eShare still expanding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTecartus, about $0.4B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTecartus was a \"Question Mark\" in Gilead Sciences, Inc. BCG terms: 2024 sales were about $0.4B, far below Yescarta, but it matters as a CAR-T asset in mantle cell lymphoma and B-ALL. The market is smaller, yet label expansion can still lift revenue from a low base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e2024 sales: about $0.4B\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTargets mantle cell lymphoma and B-ALL\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSmaller market than Yescarta\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNew indications could drive growth\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Star Drugs Keep Growth Powering Forward\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiktarvy, Descovy PrEP, Yescarta, and Trodelvy are Gilead Sciences, Inc.'s Stars: each has strong sales, leading share, and growth in HIV or oncology. In 2024, Biktarvy led at $13.4B, while Descovy PrEP, Yescarta, and Trodelvy added about $2.4B, $1.7B, and $1.3B. These assets still drive growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eBCG Role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e$13.4B\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDescovy PrEP\u003c\/td\u003e\n\u003ctd\u003e$2.4B\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYescarta\u003c\/td\u003e\n\u003ctd\u003e$1.7B\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGilead’s BCG Matrix maps HIV and Hep C cash cows, oncology stars, and pipeline question marks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG view of Gilead Sciences to spot cash cows, stars, and drag areas fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides credible source backing for Gilead Sciences, Inc., making key assumptions easy to verify and decisions faster to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpclusa, about $2.7B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpclusa is Gilead Sciences, Inc.'s core hepatitis C cash cow, with about $2.7B in 2024 sales. It sits in a mature, low-growth market, but Gilead still holds major share.\u003c\/p\u003e\n\u003cp\u003eThe brand keeps producing strong cash with limited promotion, so margins stay attractive. That makes Epclusa a classic BCG Cash Cow for funding newer pipeline bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarvoni, about $1B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarvoni remains a cash cow for Gilead Sciences, Inc., with about $1.0 billion in 2024 sales. Growth is limited because hepatitis C is now a mature, highly treated cure market, so new patient demand is thin. Even with generic pressure, Harvoni still throws off strong cash flow thanks to its legacy scale and low ongoing investment needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVemlidy, about $1B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVemlidy is a mature chronic HBV therapy with steady refill demand, and Gilead Sciences, Inc. reported about $1B in 2024 sales for the brand. Its long-term use in a defined specialty base keeps churn low and commercial volatility limited. That makes it a Cash Cow that helps support Gilead Sciences, Inc.'s margin and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLetairis, mature PAH franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLetairis is a mature pulmonary arterial hypertension brand in a niche, chronic-use market, so it needs little extra growth spend and keeps serving a small, sticky patient base. PAH affects only about 15 to 50 people per 1 million adults worldwide, which fits a high-share, low-growth cash-cow profile. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChronic therapy supports steady refills\u003c\/li\u003e\n\u003cli\u003eNiche prevalence limits growth needs\u003c\/li\u003e\n\u003cli\u003eLow promo spend fits cash-cow logic\u003c\/li\u003e\n\u003cli\u003eEstablished brand supports durable cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIts value comes less from expansion and more from repeat use in a long-term disease setting. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmBisome, mature anti-fungal brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmBisome is a mature, specialty anti-infective for serious invasive fungal infections, where mortality can exceed 30% in high-risk patients. Demand stays steady because it is medically necessary, not optional, and growth is limited. That makes it a classic Cash Cow for Gilead Sciences, Inc., with recurring cash and little need for big new spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable hospital-driven demand\u003c\/li\u003e\n\u003cli\u003eHigh clinical need, low growth\u003c\/li\u003e\n\u003cli\u003eCash flow with limited expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Cash Cows Keep Funding Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc.'s Cash Cows are mature brands that still generate strong, low-cost cash. Epclusa, Harvoni, and Vemlidy each had about $1.0B to $2.7B in 2024 sales, while Letairis and AmBisome rely on steady chronic or hospital demand. They fund newer growth bets with limited reinvestment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eCash Cow Signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpclusa\u003c\/td\u003e\n\u003ctd\u003e$2.7B\u003c\/td\u003e\n\u003ctd\u003eHigh share, mature HCV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHarvoni\u003c\/td\u003e\n\u003ctd\u003e$1.0B\u003c\/td\u003e\n\u003ctd\u003eLegacy demand, low spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGilead Sciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Gilead Sciences, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo content or missing sections—just the full, polished report ready for immediate use. Once purchased, you’ll get the same file for downloading, sharing, or presenting with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTruvada, generic HIV erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTruvada is now a Dogs asset for Gilead Sciences, Inc.: generic entry in the U.S. since 2020 and internal HIV cannibalization crushed growth. Gilead Sciences, Inc. no longer breaks out Truvada sales, which signals how small it has become versus newer HIV drugs. By 2025, it is mainly a low-growth legacy cash source.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAtripla, generic legacy HIV therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAtripla, Gilead Sciences, Inc.’s 2006 single-tablet HIV regimen, is now a classic Dog in the BCG Matrix. Generic competition and newer regimens have driven it into decline, and Gilead’s 2025 HIV revenue was led by Biktarvy and Descovy, while Atripla was not a material disclosed sales line. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStribild, genericized HIV brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStribild is an older four-drug HIV single-tablet regimen that has been overtaken by newer, safer, simpler options like Biktarvy. Its commercial case is weak in 2025 because Gilead's HIV growth is now driven by newer brands, while Stribild is genericized and contributes little strategic value. In BCG terms, it fits the Dog bucket: low growth, low share, and limited reinvestment case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eComplera\/Eviplera, mature HIV combo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eComplera\/Eviplera is a mature HIV regimen in Gilead Sciences, Inc.’s Dogs bucket: demand keeps shrinking as newer integrase-based therapies like Biktarvy take share. It is no longer a growth driver, and its role is mainly legacy maintenance, not portfolio expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy HIV combo, weak demand.\u003c\/li\u003e\n\u003cli\u003eNewer integrase regimens gained share.\u003c\/li\u003e\n\u003cli\u003eNot fit for growth portfolio.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRanexa, chronic angina franchise in decline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRanexa is a classic Dog in Gilead Sciences, Inc.'s BCG mix: an older chronic angina drug with low growth and little strategic value. After patent loss and generic entry, its market power fell sharply, and it no longer acts as a meaningful earnings driver. In Gilead Sciences, Inc.'s 2025 reporting, Ranexa is not highlighted as a material product, which fits a low-share, decline-stage asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder cardiovascular brand\u003c\/li\u003e\n\u003cli\u003eGeneric pressure erased pricing power\u003c\/li\u003e\n\u003cli\u003eLow growth, low share, low priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Aging HIV Brands: The Dogs Facing Generic Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Gilead Sciences, Inc.’s Dogs are older HIV and legacy brands with generic pressure, shrinking demand, and no material disclosed sales. Truvada, Atripla, Stribild, Complera\/Eviplera, and Ranexa sit in the low-growth, low-share bucket while Biktarvy and Descovy drive the HIV franchise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTruvada\u003c\/td\u003e\n\u003ctd\u003eGeneric since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtripla\u003c\/td\u003e\n\u003ctd\u003eNo material 2025 sales line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYeztugo, FDA approved Jun 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYeztugo (lenacapavir), FDA approved in June 2025, is a Question Mark in Gilead Sciences, Inc.’s BCG matrix: it opens a large HIV PrEP market with strong growth, but share is still early-stage. Gilead priced Yeztugo at about $28,000 a year, so uptake will hinge on access and payer wins. Gilead must spend heavily on education and rollout to turn demand into sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunlenca, niche HIV capsid inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSunlenca (lenacapavir) is a first-in-class HIV capsid inhibitor for heavily treatment-experienced adults, with twice-yearly dosing after the start-up phase. It is innovative, but its use is narrow: this niche sits far below Gilead Sciences, Inc.’s \u0026gt;$18 billion HIV franchise. That makes it a Question Mark in BCG terms, with platform value but still limited current share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivdelzi, approved 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLivdelzi (seladelpar) was approved by the US FDA in June 2024 for primary biliary cholangitis, a rare liver disease affecting about 100,000 people in the US. The market is still early, but it has room to grow because only part of the eligible pool is treated. For Gilead Sciences, Inc., this makes Livdelzi a Question Mark: growth potential is real, but share depends on fast commercial execution and physician uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGS-1720, investigational HIV long-acting program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGS-1720 is a classic Question Mark in Gilead Sciences, Inc.'s BCG mix: high upside, zero commercial share at the end of 2025 because it is still investigational. If Gilead Sciences, Inc. proves long-acting HIV dosing, this late-stage asset could strengthen a market where Gilead Sciences, Inc. already generated $19.6 billion in total revenue in 2024, with HIV as the core driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo 2025 sales yet\u003c\/li\u003e\n\u003cli\u003eHigh-risk, high-reward bet\u003c\/li\u003e\n\u003cli\u003eCould reshape HIV care\u003c\/li\u003e\n\u003cli\u003eNeeds trial success first\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGS-4182, investigational HIV long-acting program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGS-4182 is a Question Mark in Gilead Sciences, Inc. BCG view: it targets the expanding HIV prevention and treatment market, but it is still pre-commercial and has no revenue base. Gilead Sciences, Inc. reported 2025 product revenue of about $28.8 billion, so GS-4182 could matter if it converts clinical progress into sales. If approved, it could add a new long-acting growth leg.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-commercial, zero revenue today\u003c\/li\u003e\n\u003cli\u003eFits a growing HIV market\u003c\/li\u003e\n\u003cli\u003ePotential future growth driver\u003c\/li\u003e\n\u003cli\u003eHigh upside, execution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Question Marks: Big Upside, But Commercial Proof Still Needed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc.’s Question Marks are mostly early-stage HIV and specialty assets with high upside but little current share. Yeztugo and Sunlenca target the HIV market, while Livdelzi is still scaling in rare liver disease; GS-1720 and GS-4182 remain pre-commercial. The theme is clear: strong science, but revenue depends on payer access, launch speed, and trial wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYeztugo\u003c\/td\u003e\n\u003ctd\u003eFDA approved\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSunlenca\u003c\/td\u003e\n\u003ctd\u003eNiche use\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi\u003c\/td\u003e\n\u003ctd\u003eEarly launch\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGS-1720\u003c\/td\u003e\n\u003ctd\u003eInvestigational\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191843725577,"sku":"gild-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gild-bcg-matrix.webp?v=1783678513","url":"https:\/\/dcfanalyst.com\/products\/gild-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}